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Apolipoprotein A-I (apoA-I) and high-density lipoproteins (HDL) mediate reverse
cholesterol transport out of cells. Furthermore, HDL has additional protective functions,
which include anti-oxidative, anti-inflammatory, anti-apoptotic, and vasoprotective
effects. In contrast, HDL can become dysfunctional with a reduction in both cholesterol
efflux and anti-inflammatory properties in the setting of disease or the acute phase
response. These paradigms are increasingly being recognized to be active in the
pulmonary system, where apoA-I and HDL have protective effects in normal lung health,
as well as in a variety of disease states, including acute lung injury (ALI), asthma, chronic
obstructive pulmonary disease, lung cancer, pulmonary arterial hypertension, pulmonary
fibrosis, and viral pneumonia. Similar to observations in cardiovascular disease, however,
HDL may become dysfunctional and contribute to disease pathogenesis in respiratory
disorders. Furthermore, synthetic apoA-I mimetic peptides have been shown to have
protective effects in animal models of ALI, asthma, pulmonary hypertension, and
influenza pneumonia. These findings provide evidence to support the concept that
apoA-I mimetic peptides might be developed into a new treatment that can either
prevent or attenuate the manifestations of lung diseases, such as asthma. Thus, the
lung is positioned to take a page from the cardiovascular disease playbook and utilize
the protective properties of HDL and apoA-I as a novel therapeutic approach.
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High-density lipoprotein particles (HDL) and its major protein, apolipoprotein A-I (apoA-I), play
key roles in attenuating the risk of atherosclerotic cardiovascular disease (Navab et al., 2011;
Kingwell et al., 2014; Rader and Hovingh, 2014; Rosenson et al., 2016). A key mechanism by
which HDL decreases atherosclerosis is by mediating reverse cholesterol eﬄux out of cells. ApoA-
I, which is primarily produced in the liver and small intestine, can form nascent, discoidal HDL
particles by complexing with unesterified cholesterol and phospholipids that have been eﬄuxed
via the ATP-binding cassette subfamily A member 1 (ABCA1) transporter (Kingwell et al., 2014).
Following esterification and transport of cholesterol to the particle core by lecithin-cholesterol
acyltransferase, spheroidal HDL particles can eﬄux additional cholesterol and phospholipids from
cells via ABCG1 and scavenger receptor class B member 1 (SRB1). In addition, HDL has anti-
oxidative, anti-inflammatory, anti-apoptotic, and vasoprotective properties (Navab et al., 2011;
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Rosenson et al., 2016). An anti-inflammatory function of HDL is
its ability to reduce the cholesterol content of immune cells by
decreasing receptor localization and signaling within lipid rafts
(Catapano et al., 2014). However, in the setting of disease or
the acute-phase response, HDL can become dysfunctional, with
diminished cholesterol eﬄux and anti-inflammatory properties
(Kingwell et al., 2014; Rosenson et al., 2016). It is increasingly
recognized that both HDL (Figure 1) and apoA-I (Figure 2)
similarly, play important roles in modulating normal lung
health and disease. Thus, paradigms that have long been
applied to atherosclerotic cardiovascular disease may also be
relevant for pulmonary disorders, including acute lung injury
(ALI), asthma, chronic obstructive pulmonary disease, lung
cancer, pulmonary fibrosis, pulmonary hypertension, and viral
pneumonia.
NORMAL LUNG DEVELOPMENT AND
LUNG LIPID HOMEOSTASIS
Levels of mRNA encoding apoA-I, apoA-II, and apoH, are
expressed at higher levels in the murine fetal lung than
the adult lung, which suggests that pulmonary apolipoprotein
production modulates lung maturation via lipid metabolism and
transport during embryonic development (Provost et al., 2009).
Apolipoprotein A-I and apoA-II are primarily expressed by
capillary-like structures during gestational days 15.5–18.5 (Cote
et al., 2011). In the adult lung, apoA-I is expressed by alveolar
epithelial cells and alveolar macrophages, while the ABCA1
transporter is expressed by type I and type II alveolar epithelial
cells, alveolar macrophages, pulmonary vascular endothelial cells
(PVECs), and airway smooth muscle cells (Bortnick et al., 2003;
Bates et al., 2008; Delvecchio et al., 2008; Kim et al., 2010; Dai
et al., 2012, 2014; Park et al., 2013).
The apoA-I/ABCA1 pathway maintains normal lipid
homeostasis in the lung by mediating the release of lipids from
type I alveolar epithelial cells to apoA-I (Bates et al., 2008).
Similarly, ABCA1 expression by type II alveolar epithelial cells
facilitates the removal of cholesterol mass and reduces basal rates
of surfactant secretion (Bortnick et al., 2003). The important role
of ABCA1 in maintaining normal lipid homeostasis in the lung
is further highlighted by the finding that alveolar macrophages
and type II alveolar epithelial cells from Abca1-deficient mice
are enriched with cholesterol (McNeish et al., 2000; Bates
et al., 2005). Furthermore, Abca1-deficient mice have abnormal
lung morphology characterized by alveolar proteinosis, as well
as hypertrophy and hyperplasia of type II alveolar epithelial
cells.
Studies utilizing Apoa1-deficient mice have shown an
important role for apoA-I in attenuating basal levels of
inflammation and oxidative stress in the lung. For example, HDL
from Apoa1-deficient mice oxidizes at a faster rate than HDL
from wild-type mice (Wang et al., 2010). Furthermore, Apoa1-
deficient mice display increased systemic oxidative stress, lung
inflammation, and collagen deposition. Basal levels of airway
hyperresponsiveness (AHR) are also increased in Apoa1-deficient
mice, while pulmonary artery vasodilatation is impaired. Thus,
apoA-I plays an important role in maintaining normal lung
health.
ACUTE LUNG INJURY (ALI) AND ACUTE
RESPIRATORY DISTRESS SYNDROME
(ARDS)
Acute respiratory distress syndrome describes a clinical entity of
severe lung dysfunction that reflects an acute inflammatory lung
injury secondary to a variety of causative factors, such as bacterial
infection (Bellani et al., 2016). A beneficial property of apoA-
I is its ability to directly bind and neutralize lipopolysaccharide
(LPS), which is derived from the cell walls of gram-negative
bacteria, as well as lipoteichoic acid (LTA), which is a cell
wall component of gram-positive bacteria (Emancipator et al.,
1992; Ma et al., 2004; Jiao and Wu, 2008; Henning et al., 2011;
Van Linthout et al., 2011; Sharifov et al., 2013). The domains
that mediate LPS binding are located in the carboxy-terminus
of apoA-I (Henning et al., 2011). Apolipoprotein A-I can also
associate with the lipopolysaccharide-binding protein, which
binds and neutralizes LPS (Wurfel et al., 1994).
Both murine and human studies have provided evidence for a
protective function of apoA-I in ALI and ARDS. Apoa1-deficient
mice have increased neutrophil recruitment to the lung following
inhalation of LPS or direct instillation of CXCL1, which can be
attenuated by administration of the L-4F apoA-I mimetic peptide
by a mechanism involving inhibition of CXCR2-mediated
neutrophil chemotaxis (Madenspacher et al., 2012). Similarly,
administration of apoA-I mimetic peptides, human apoA-I, or
over-expression of human apoA-I via a recombinant adenoviral
vector, protected rodents from developing neutrophilic airway
inflammation and ALI in models of LPS- or LTA-mediated
systemic inflammation (Yan et al., 2006; Jiao and Wu, 2008;
Li et al., 2008; Van Linthout et al., 2011; Kwon et al., 2012;
Sharifov et al., 2013). Treatment of LPS-stimulated human
blood with the L-4F apoA-I mimetic peptide has suppressed
endotoxin activity and IL-6 secretion, as well as preserved
paraoxonase function (Sharifov et al., 2013). The L-4F apoA-I
mimetic peptide also inhibited cellular activation and superoxide
formation when human neutrophils were exposed to serum
obtained from subjects with ARDS. Administration of human
HDL to mice has also attenuated LPS-induced ALI (Xiao et al.,
2008).
Human translational studies have suggested a correlation
between the APOA1 gene and the risk of sepsis-associated ALI.
Carriage of the APOA1 -75 AA genotype in the APOA1 promoter,
which has reduced promoter activity as compared to the major
G allele, has been associated with a higher risk of ALI following
cardiopulmonary bypass surgery (Smith et al., 1992; Tu et al.,
2013). The rs11216153 SNP in the APOA1 gene has also been
associated with ALI risk in subjects with sepsis, with the GG
genotype and G allele being more common among ALI patients
than controls (Hao and He, 2014). However, since this SNP is
located in a non-coding region of the APOA1 gene, it is unclear
if the association is with the APOA1 gene itself or variants from
nearby genes.
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FIGURE 1 | Roles of normal and dysfunctional high-density lipoproteins (HDL) in the lung. HDL has been associated with protective effects in the normal
lung (Cirillo et al., 2002), as well as in the setting of asthma (Barochia et al., 2015, 2016; Rastogi et al., 2015) and lung cancer (Kucharska-Newton et al., 2008; Chi
et al., 2014; Chandler et al., 2016), which may reflect its anti-inflammatory and anti-oxidant properties. In contrast, dysfunctional HDL particles may promote disease
severity in the setting of chronic obstructive pulmonary disease (Burkart et al., 2014) and viral pneumonia (Van Lenten et al., 2001). HDL particles in pulmonary
arterial hypertension have been found to have either protective effects (Heresi et al., 2010; Sharma et al., 2014), or dysfunctional, pro-inflammatory properties (Ross
et al., 2015).
ASTHMA
Murine studies have demonstrated a protective role for
an apoA-I/ABCA1 pathway in the pathogenesis of asthma.
Apoa1-deficient mice that were sensitized and challenged
with ovalbumin developed augmented neutrophilic airway
inflammation that was primarily mediated by the increased
production of granulocyte colony stimulating factor (G-CSF) by
alveolar macrophages (AMφs) and PVECs, as well as by the
increased expression of IL-17A, TNF-α, CXCL5, and VCAM-1
(Dai et al., 2012). Furthermore, G-CSF can increase the number
of tissue neutrophils by attenuating apoptosis, which prolongs
neutrophil survival in the lung (Matute-Bello et al., 1997).
Similarly, transgenic mice that expressed human ABCA1 under
the control of the Tie2 promoter in both PVECs and AMφs had
decreased ovalbumin-induced neutrophilic airway inflammation
that was in part mediated by the reduced expression of G-CSF
(Dai et al., 2014).
Murine studies have further demonstrated that apoA-I
mimetic peptides can suppress allergen-mediated airway
inflammation. Administration of the 5A apoA-I mimetic
peptide inhibited allergen-mediated increases in neutrophilic
airway inflammation in Apoa1-deficient mice (Dai et al.,
2012). Similarly, administration of the 5A apoA-I mimetic
peptide to wild-type mice attenuated the development of
allergen-induced airway inflammation and AHR, and also
reduced airway remodeling responses, including mucous cell
metaplasia and collagen gene expression (Yao et al., 2011).
Likewise, administration of the D-4F apoA-I mimetic peptide
suppressed oxidative stress, eosinophilic airway inflammation,
AHR, and total immunoglobulin E levels in allergen-challenged
wild-type mice (Nandedkar et al., 2011). Administration of
human apoA-I to allergen-challenged wild-type mice similarly,
suppressed airway inflammation, AHR, dendritic cell migration
to the lung, and reduced the release of IL-25, IL-33, and TSLP
(thymic stromal lymphopoietin) by airway epithelial cells (Park
et al., 2013). In addition, apoA-I administration promoted the
recovery of disrupted airway epithelial tight junction proteins
and increased the pro-resolution lipid mediator, lipoxin A4, in
both mice and humans. Human translational studies have also
supported a role for apoA-I in asthma. For example, apoA-I levels
in bronchoalveolar lavage fluid (BALF) from mild-to-moderate
asthmatics are five-fold lower than in BALF from normal control
subjects (Park et al., 2013). Similarly, apoA-I levels are reduced in
BALF from ovalbumin-challenged wild-type mice as compared
to control mice that were sensitized and challenged with saline
(Dai et al., 2012).
Clinical studies have shown that higher systemic levels of HDL
and apoA-I are associated with less severe airflow obstruction
in both healthy individuals and asthmatics. For example, in an
analysis of subjects without respiratory disease who participated
in the Third National Health and Nutrition Survey, both HDL
and apoA-I were positively associated with FEV1 (Cirillo et al.,
2002). Similarly, both HDL and apoA-I were positively correlated
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FIGURE 2 | Apolipoprotein A-I (apoA-I) has multiple protective functions in the normal and diseased lung. Apolipoprotein A-I has multiple protective and
beneficial functions in the normal lung (Wang et al., 2010) and in a variety of pulmonary disorders, including acute lung injury (ALI) (Yan et al., 2006; Jiao and Wu,
2008; Li et al., 2008; Van Linthout et al., 2011; Kwon et al., 2012; Madenspacher et al., 2012; Sharifov et al., 2013), asthma (Nandedkar et al., 2011; Dai et al.,
2012; Yao et al., 2011; Park et al., 2013), cigarette smoke-induced emphysema (Kim et al., 2016), influenza pneumonia (Van Lenten et al., 2002, 2004), lung cancer
(Zamanian-Daryoush et al., 2013), pulmonary hypertension (Sharma et al., 2014) and idiopathic pulmonary fibrosis (IPF) (Kim et al., 2010; Lee et al., 2013). Data
addressing the role of apoA-I in lung disease have primarily been generated in experimental animal models, although several studies have suggested that apoA-I
may be associated with decreased disease severity in subjects with asthma (Barochia et al., 2015, 2016) and IPF (Kim et al., 2010), which are indicated.
with FEV1 in a cohort of atopic asthmatics at the National Heart,
Lung, and Blood Institute (Barochia et al., 2015). Furthermore,
the positive association with FEV1 in atopic asthmatics was
mediated by the subset of large HDLNMR particles, as quantified
by nuclear magnetic resonance (NMR) spectroscopy. Higher
circulating levels of HDL have also been correlated with lower
blood eosinophil counts in asthma, which is a biomarker of type
2 inflammation (Barochia et al., 2016). The negative association
between serum HDL and absolute blood eosinophil counts was
again mediated by the subset of large HDLNMR particles. Of note,
large HDLNMR particles have also been associated with a lower
risk of incident cardiovascular disease and type 2 diabetes in
women (Mora et al., 2009, 2010). Another correlation between
HDL and inflammation was identified in obese, adolescent
asthmatics who had an inverse association with the number of
patrolling monocytes, which is an innate immune cell population
that can be rapidly recruited to the lung during inflammation
(Rastogi et al., 2015). Collectively, these studies suggest that
apoA-I and HDL may modulate both airflow obstruction and
airway inflammation in asthma.
CHRONIC OBSTRUCTIVE PULMONARY
DISEASE (COPD)
Chronic obstructive pulmonary disease is caused by inhalation
of noxious particles or gases, such as cigarette smoke, with
resultant chronic inflammation and airflow limitation that is
not fully reversible (Celli et al., 2015). ApoA-I and HDL
have context-dependent effects in COPD. For example, apoA-I
has a protective role in preventing cigarette-smoke induced
emphysema. In a murine model of cigarette smoke-induced
lung disease, transgenic mice that conditionally over-expressed
the human APOA1 gene in alveolar epithelial cells were
protected from developing emphysema (Kim et al., 2016). In
particular, apoA-I over-expression attenuated cigarette smoke-
induced increases in lung inflammation, oxidative stress,
metalloproteinase activation, and lung cell apoptosis by a
mechanism that involved the reduced translocation of Fas
to lipid rafts, which decreased the formation of death-
inducing signaling complexes and caspase-8 activation. Cigarette
smoke exposure also decreased the amount of apoA-I in the
lungs of wild-type mice, which suggests that the loss of its
protective function may contribute to emphysema pathogenesis
(Kim et al., 2016). Similarly, lung tissue from patients with
moderate emphysema contained reduced amounts of apoA-
I as compared to lung tissue from non-smoking subjects.
Furthermore, the amount of apoA-I was reduced in induced
sputum samples of COPD patients as compared to healthy
smokers (Nicholas et al., 2010). These studies suggest that the
reduction in lung apoA-I levels may contribute to lung disease
in COPD.
High-density lipoproteins may also have a therapeutic role in
emphysema caused by alpha-1-antitrypsin deficiency. Alpha-1-
antitrypsin is a component of HDL that confers anti-protease
properties that inhibit leukocyte elastase (Ortiz-Munoz et al.,
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2009). Intravenous administration of HDL enriched with alpha-
1-antitrypsin to cigarette smoke-exposed mice prevented the
development of pulmonary emphysema and also reduced the
numbers of BALF neutrophils and macrophages, as well as
BALF levels of IL-6, TNF-α (tumor necrosis factor), and MCP-
1 (monocyte chemoattractant protein-1) (Moreno et al., 2014).
BALF fibronectin degradation and matrix metalloproteinase
(MMP-2 and MMP-9) activity were also reduced. The protective
effects of intravenous administration of HDL complexed with
alpha-1-antitrypsin were superior to those of HDL or alpha-1-
antitrypsin alone, which suggested that combining HDL with
alpha-1-antitrypsin might be more effective than the current
strategy of alpha-1-antitrypsin augmentation therapy.
In contrast to the ability of apoA-I to attenuate the induction
of cigarette smoke-induced emphysema in murine models,
HDL has been associated with increased disease severity in
human subjects with emphysema. In the MESA (Multi-Ethnic
Study of Atherosclerosis) COPD study, higher plasma HDL
levels were associated with a lower FEV1/FVC ratio, which
indicated more severe airflow obstruction (Burkart et al., 2014).
Furthermore, higher HDL levels were associated with greater
percent emphysema on chest computed tomography scans. This
suggests that HDL may not be protective in the setting of
established emphysema, but instead may have dysfunctional
properties (Navab et al., 2011; Kingwell et al., 2014; Rader and
Hovingh, 2014; Rosenson et al., 2016).
LUNG CANCER
Potential anti-tumorigenic effects of apoA-I have been identified
using murine neoplasia models that showed a dose-dependent
inhibition of Lewis lung tumor growth rates with increasing
apoA-I levels (Zamanian-Daryoush et al., 2013). Potential
anti-neoplastic effects of apoA-I included inhibition of
angiogenesis and MMP-9 activity, accumulation of myeloid-
derived suppressor cells in tumor beds, and expression of the
anti-apoptotic protein, survivin. In addition apoA-I, was found
to promote the anti-neoplastic effects of tumor-associated
CD11b+ macrophages.
The prospective Atherosclerosis Risk in Communities Study
found an inverse association between serum HDL-C levels and
incident lung cancer over a 13 years period in former smokers,
but not in current smokers (Kucharska-Newton et al., 2008).
Similarly, an inverse association between low serum HDL-C
and neoplasia was seen with other cancers, which suggests a
common mechanism by which low HDL-C levels may promote
an environment that is permissive to neoplasia. Another study
of non-small cell lung cancer (NSCLC) subjects found that serum
HDL-C levels were significantly decreased as compared to normal
controls (Chi et al., 2014). Furthermore, NSCLC subjects with
low levels of HDL-C had significantly reduced cumulative 5-year
survival rates as compared to individuals with normal HDL-
C levels. The Women’s Health Study prospectively associated
incident cancer rates and cancer mortality with circulating lipid
biomarkers in health professionals (Chandler et al., 2016). This
study found that higher circulating levels of apoA-I and HDL
were inversely associated with the risk of both total cancer and
lung cancer. Collectively, these data support an anti-neoplastic
role for apoA-I and HDL in lung cancer.
PULMONARY HYPERTENSION
Apolipoprotein A-I and HDL may also have context-dependent
effects in pulmonary hypertension. For example, administration
of the 4F apoA-I mimetic peptide rescued preexisting pulmonary
hypertension in rodent models by increasing the expression of the
microRNA, mmu-miR-193, via the retinoid X receptor α (Sharma
et al., 2014). Induction of mmu-miR-193 inhibited the expression
of insulin-like growth factor-1 receptor and lipoxygenases (e.g.,
ALOX5, ALOX12, and ALOX15), which suppressed pulmonary
artery smooth muscle cell proliferation.
Human translational studies have shown that HDL may be
associated with disease severity and outcome in pulmonary
arterial hypertension (PAH). For example, a study of PAH
subjects at the Cleveland Clinic found significantly lower serum
levels of HDL-C as compared to control subjects (Heresi
et al., 2010). Furthermore, when subjects were stratified by
HDL-C levels, those with HDL-C greater than 35 mg/dl had
no mortality and a longer time to clinical worsening over
a period of 1.5 years, which was independent of underlying
cardiovascular risk factors, insulin resistance, or PAH disease
severity. Furthermore, PAH subjects with HDL-C levels that
exceeded 35 mg/dl had less systemic inflammation, as indicated
by lower levels of serum C-reactive protein, TNF-α, IL-17A,
CCL2, and ICAM-1. In contrast, another study of subjects with
“idiopathic” PAH (IPAH) or PAH “associated” with underlying
etiologies (APAH) found that HDL had been converted to a
dysfunctional, pro-inflammatory particle which increased the
chemotaxis of peripheral blood monocytes as compared to
normal HDL (Ross et al., 2015). Ex vivo treatment with the
4F apoA-I mimetic peptide significantly improved, but did not
completely attenuate, the dysfunctional pro-inflammatory HDL
phenotype. In addition, HDL fractions from IPAH and APAH
subjects had increased levels of multiple eicosanoids. Therefore,
additional studies will be needed to further define the roles of
HDL in PAH.
PULMONARY FIBROSIS
Idiopathic pulmonary fibrosis (IPF) is a disease of chronic,
progressive fibrosing interstitial pneumonia that occurs primarily
in older adults (Raghu et al., 2015). Reduced amounts of apoA-I
have been found in BALF from subjects with IPF as compared
to normal controls (Kim et al., 2010). Furthermore, apoA-
I levels in BALF from IPF patients were inversely correlated
with both clinical severity scores and the percentage of foamy
macrophages. The role of apoA-I in pulmonary fibrotic disease
was subsequently assessed in murine models, where intranasal
administration of human apoA-I protein suppressed the number
of BALF inflammatory cells, histologic evidence of inflammatory
cell infiltration, and lung collagen deposition. Furthermore,
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apoA-I levels were reduced in BALF from bleomycin-challenged
mice. Similarly, transgenic mice that over-expressed human
apoA-I in alveolar epithelial cells were protected from silica-
induced lung inflammation and fibrotic nodule formulation by
a mechanism that might involve increased expression of lipoxin
A4 (Lee et al., 2013). Collectively, these data suggest that apoA-I
has a protective effect in IPF.
VIRAL PNEUMONIA
Apolipoprotein A-I and HDL also modulate the pathogenesis
of influenza A infection. HDL isolated from mice infected with
influenza A is dysfunctional with reduced anti-inflammatory and
anti-oxidant properties that, in part, reflected decreased activity
of paraoxonase and platelet-activating factor acetylhydrolase,
as well as increased ceruloplasmin, which is a potent oxidant
(Van Lenten et al., 2001). In contrast, apolipoprotein J levels
in HDL were increased, which might promote cholesterol
eﬄux from macrophages. Administration of the D-4F apoA-I
mimetic peptide to mice infected with influenza A attenuated
lung inflammation, suppressed IL-6 production, and prevented
macrophage trafficking into arteries (Van Lenten et al., 2002).
The D-4F apoA-I mimetic peptide also had antiviral activity that
reduced influenza titers by more than 50%. Similarly, the D-
4F apoA-I mimetic peptide inhibited the production of oxidized
phospholipids, IFN-α/β, and IL-6 by an alveolar epithelial cell
line and also suppressed viral titers and caspase activity (Van
Lenten et al., 2004). Collectively, these findings suggest that
apoA-I mimetic peptides may have therapeutic potential for the
treatment of influenza A pneumonia.
CONCLUSION
An increasing body of evidence supports the concept that HDL,
and particularly apoA-I, modulate the pathogenesis and severity
of lung disease. This may involve both the systemic effects of HDL
in the circulation, as well as the local production of apoA-I in
the lung. Although normal HDL has multiple protective effects,
HDL may become dysfunctional in the setting of lung disease
and no longer attenuate disease manifestations. Furthermore,
data from murine models has suggested that small apoA-I
mimetic peptides, which are based upon the α-helical structure
of apoA-I, may be developed into a novel therapy for lung
disease. In particular, administration of 5A and D-4F apoA-
I mimetic peptides has protective effects in animal models of
ALI, asthma, pulmonary hypertension, and influenza pneumonia
(Yao et al., 2011; Van Lenten et al., 2002; Dai et al., 2012;
Kwon et al., 2012; Madenspacher et al., 2012; Sharifov et al.,
2013; Sharma et al., 2014). Furthermore, the D-4F and L-4F
apoA-I mimetic peptides have already been evaluated in human
subjects with cardiovascular disease and have been well-tolerated
(Dunbar et al., 2007; Bloedon et al., 2008; Watson et al., 2011).
This provides evidence to support the concept that inhalational
administration of apoA-I mimetic peptides to provide site-
directed delivery to the lung may attenuate the manifestations of
pulmonary disease. Consistent with this concept, our laboratory
is currently working toward advancing an inhaled formulation of
the 5A apoA-I mimetic peptide to clinical trials that will assess its
safety and role for the treatment of asthma. Therefore, the lung
may benefit from taking a page from the cardiovascular disease
playbook and apply the protective properties of HDL and apoA-I
as a novel therapeutic approach for pulmonary disease.
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